Ireland’s restrictive interpretation of EU data rules is hindering cancer trials, with only 11 out of 3,500 industry-sponsored trials in the first half of 2024 including Irish patients. The fragmented system for managing data in Irish hospitals is impacting patient access to trials and damaging the country’s reputation as a research destination. Public opinion in Ireland supports a less restrictive approach to data protection, with a majority willing to share health information for research. Cancer Trials Ireland and the Irish Cancer Society are calling for a national body to define healthcare guidelines to streamline the process and attract more clinical trial sponsors to Ireland.
Source link
Interpretation of GDPR hindering cancer trials here
